Additionally, AZD1775 has demonstrated potential to overcome resistance to breast cancer therapies such as trastuzumab (Sand et al., 2020) and CDK4/6i (Fallah et al., 2021), making it an attractive candidate among small-molecule drugs. Here, CDK4 is linked to breast carcinoma.